AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 14532798
Drug: Periprostatic infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periprostatic infiltration with 10 ml 1% lidocaine
Trial: 8986487
Drug: Continuous zero‐balanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous zero‐balanced hemofiltration (HF) without dialysis (ultrafiltrate rate 2 l/h)
Trial: 31425951
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (100 μg or 4000 IU daily for 12 weeks)
Trial: 27619558
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with gemigliptin 50 mg qd + metformin 1000 to 2000 mg qd
Trial: 27619558
Drug: Gemigliptin monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemigliptin monotherapy 50 mg qd
Trial: 27619558
Drug: Metformin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin monotherapy 1000 to 2000 mg qd
Trial: 27343309
Drug: Antagonist protocol
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Antagonist protocol
Trial: 24746976
Drug: ONS-EPA (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONS-EPA (oral nutritional supplement containing eicosapentaenoic acid)
Trial: 11800062
Drug: Valsartan 80
RxNorm normalized name: valsartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 80 mg combined with hydrochlorothiazide (HCTZ) 12.5 mg
Trial: 10082603
Drug: Tissue engineering
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tissue engineering materials (e.g., Apligraf, Integra)
Trial: 10082603
Drug: Polymeric wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymeric wound dressings (e.g., Tegaderm, Opsite)
Trial: 10082603
Drug: Dermal replacements
RxNorm normalized name: Dermal-Soothe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dermal replacements (e.g., reconstituted collagen and chondroitan sulfate)
Trial: 8151608
Drug: Ketanserin 40
RxNorm normalized name: ketanserin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin 40 mg twice daily after six weeks
Trial: 8151608
Drug: Ketanserin 40
RxNorm normalized name: ketanserin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin 40 mg twice daily after ten days
Trial: 3340420
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine injection for myofascial trigger points
Trial: 3340420
Drug: Intravenous naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous naloxone (10 mg)
Trial: 27247177
Drug: Paliperidone Palmitate
RxNorm normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paliperidone Palmitate (PP) 39-234 mg
Trial: 27247177
Drug: Haloperidol Decanoate
RxNorm normalized name: Haloperidol Decanoate
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol Decanoate (HD) 25-200 mg
Trial: 25896862
Drug: MRI-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRI-guided treatment strategy
Trial: 25896862
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment strategy
Trial: 21041965
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (25 females, no treatment)
Trial: 15536230
Drug: Topiramate (96
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (96 mg/d)
Trial: 15536230
Drug: Topiramate (192
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (192 mg/d)
Trial: 11437473
Drug: NN703 (tabimorelin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NN703 (tabimorelin) 1.71 mg/kg
Trial: 11032702
Drug: NN703 (tabimorelin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NN703 (tabimorelin) 3.0 mg/kg
Trial: 11437473
Drug: NN703 (tabimorelin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NN703 (tabimorelin) 4.5 mg/kg
Trial: 11437473
Drug: NN703 (tabimorelin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NN703 (tabimorelin) 6.86 mg/kg
Trial: 9541440
Drug: Trabeculectomy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabeculectomy with intraoperative 0.2mg/ml MMC
Trial: 9541440
Drug: Trabeculectomy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabeculectomy with intraoperative 0.4mg/ml MMC
Trial: 1464895
Drug: Trandolapril 4
RxNorm normalized name: trandolapril 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril 4 mg
Trial: 7527100
Drug: Trandolapril (0.5-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril (0.5-4 mg range)
Trial: 29477665
Drug: vemurafenib 960
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: vemurafenib 960 mg tablets twice daily for 52 weeks
Trial: 25795646
Drug: Fingolimod 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fingolimod 1.25 mg/day
Trial: 25795646
Drug: Placebo to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to Fingolimod 0.5 mg/day
Trial: 25795646
Drug: Placebo to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to Fingolimod 1.25 mg/day
Trial: 23764639
Drug: Full PopART
RxNorm normalized name: Full Marks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full PopART intervention strategy including home-based HIV testing, linkage to care, universal antiretroviral therapy, voluntary medical male circumcision, diagnosis and treatment of STIs, behavioral counseling, and condom distribution.
Trial: 21940595
Drug: FR-MDM (fortified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FR-MDM (fortified rice midday meal with 19 mg Fe)
Trial: 11160635
Drug: Caffeine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (400 mg/70 kg)
Trial: 11160635
Drug: Nicotine (0.75,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (0.75, 1.5, and 3.0 mg/70 kg)
Trial: 11160635
Drug: Caffeine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (150 mg/70 kg)
Trial: 8069732
Drug: Subcutaneous erythropoietin
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous erythropoietin (150 U/Kg/wk to 180 U/Kg/wk)
Trial: 8069732
Drug: Intravenous erythropoietin
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous erythropoietin (75 U/Kg/wk to 90 U/Kg/wk)
Trial: 8069732
Drug: Subcutaneous erythropoietin
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous erythropoietin (for CAPD patients)
Trial: 8069732
Drug: Subcutaneous and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous and intravenous erythropoietin (various doses)
Trial: 8069732
Drug: Subcutaneous erythropoietin
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous erythropoietin
Trial: 3056073
Drug: 4-Methylpyrazole 10
RxNorm normalized name: 4-methylpyrazol
DrugBank: Fomepizole (DB01213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-Methylpyrazole 10 mg/kg
Trial: 3056073
Drug: 4-Methylpyrazole 20
RxNorm normalized name: 4-methylpyrazol
DrugBank: Fomepizole (DB01213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-Methylpyrazole 20 mg/kg
Trial: 3056073
Drug: 4-Methylpyrazole 50
RxNorm normalized name: 4-methylpyrazol
DrugBank: Fomepizole (DB01213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-Methylpyrazole 50 mg/kg
Trial: 3056073
Drug: 4-Methylpyrazole 100
RxNorm normalized name: 4-methylpyrazol
DrugBank: Fomepizole (DB01213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-Methylpyrazole 100 mg/kg
Trial: 27287389
Drug: 21mg/day nicotine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21mg/day nicotine patch and four brief behavior counseling sessions over 8 weeks
Trial: 15143375
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch therapy
Trial: 23612399
Drug: Neuromidin (ipidacrinum)
RxNorm normalized name: Neurokinin p
DrugBank: Substance P (DB19198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuromidin (ipidacrinum) therapy for 2 months
Trial: 16450017
Drug: Combined folic
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined folic acid 2.5 mg, vitamin B6 50 mg, and vitamin B12 1 mg daily
Trial: 8466836
Drug: Non-treatment control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-treatment control group (N = 29)
Trial: 29035602
Drug: Dextrose (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose (1 g/kg body mass)
Trial: 29035602
Drug: Modified Amylomaize-7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Amylomaize-7 (1 g/kg body mass)
Trial: 28003294
Drug: Non-operative management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-operative management (NOM) with antibiotic therapy alone
Trial: 28003294
Drug: Operative management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative management with prophylactic antibiotics and appendicectomy
Trial: 29901635
Drug: Rapamycin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapamycin treatment
Trial: 22578337
Drug: Becaplermin gel
RxNorm normalized name: becaplermin Topical Gel
DrugBank: Becaplermin (DB00102)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Becaplermin gel (Regranex(®))
Trial: 15966757
Drug: Modafinil 800
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Modafinil 800 mg/day
Trial: 2556433
Drug: Serotype 1
RxNorm normalized name: Aspergillus fumigatus serotype 1 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotype 1 reassortant vaccine
Trial: 2556433
Drug: Serotype 2
RxNorm normalized name: Pneumococcal polysaccharide serotype 23F
DrugBank: Streptococcus pneumoniae type 23f capsular polysaccharide antigen (DB10340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotype 2 reassortant vaccine
Trial: 2556433
Drug: Serotype 3
RxNorm normalized name: HUMAN ADENOVIRUS B SEROTYPE 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotype 3 (rhesus rotavirus) vaccine
Trial: 2556433
Drug: Bivalent preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent preparation (serotypes 1 and 3) vaccine
Trial: 28543302
Drug: TOBY therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TOBY therapy plus treatment-as-usual (n=41)
Trial: 28543302
Drug: treatment-as-usual (n=39)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment-as-usual (n=39)
Trial: 21236483
Drug: Aliskiren plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren plus amlodipine (150 mg aliskiren plus 5 mg amlodipine)
Trial: 21236483
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (300 mg aliskiren plus 10 mg amlodipine)
Trial: 19120336
Drug: Formulation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation with 0.5% benzyl nicotinate (BN) and 10% fat
Trial: 19120336
Drug: Formulation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation with 0.3% betamethasone valerate (BV) and low fat content
Trial: 19120336
Drug: Formulations with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulations with higher fat content (not specified)
Trial: 17538086
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (15 mg temsirolimus weekly + 6 million U interferon alfa three times weekly)
Trial: 17538086
Drug: Interferon alfa
RxNorm normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa (3 million U subcutaneously three times weekly, increasing to 18 million U)
Trial: 14742392
Drug: Prophylactic intravenous
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic intravenous ephedrine
Trial: 10360849
Drug: Naloxone (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (0.8 mg/15 min followed by 0.4 mg/h) + Ketamine (0.3 mg x kg(‐1) x 15 min(‐1) followed by 0.3 mg x kg(‐1) x h(‐1))
Trial: 10360849
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Ketamine (0.3 mg x kg(‐1) x 15 min(‐1) followed by 0.3 mg x kg(‐1) x h(‐1))
Trial: 6125164
Drug: metoprolol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoprolol (1 mg i.v.)
Trial: 6125164
Drug: oxprenolol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxprenolol (1 mg i.v.)
Trial: 6125164
Drug: propranolol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propranolol (1 mg i.v.)
Trial: 29383569
Drug: Levetiracetam extended-release
RxNorm normalized name: Levetiracetam Extended-Release Tablets
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam extended-release (ER) tablets
Trial: 29383569
Drug: Levetiracetam ER
RxNorm normalized name: LevETIRAcetam ER
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam ER tablets with food
Trial: 29383569
Drug: Levetiracetam immediate-release
RxNorm normalized name: levetiracetam Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam immediate-release (IR) tablets
Trial: 20181806
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (Atorvastatin + Fish oils)
Trial: 10077348
Drug: Triiodothyronine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triiodothyronine administration
Trial: 10077348
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of GH and triiodothyronine
Trial: 7554199
Drug: Warfarin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin treatment group
Trial: 31519475
Drug: Clobazam (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clobazam (40 mg)
Trial: 21224820
Drug: Heparin-coated ECC-set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated ECC-set (group B)
Trial: 21224820
Drug: Heparin-coated ECC-set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated ECC-set (group C)
Trial: 16995587
Drug: Low-dose ACTH
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ACTH test (LDT)
Trial: 16995587
Drug: Standard-dose ACTH
RxNorm normalized name: ACTH
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-dose ACTH test (SDT)
Trial: 16995587
Drug: Budesonide (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (400 μg or 600 μg daily doses)
Trial: 16995587
Drug: 24-hour urinary
RxNorm normalized name: Urinary hCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-hour urinary free cortisol excretion
Trial: 9292541
Drug: RheothRx (poloxamer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RheothRx (poloxamer 188) Injection
Trial: 8038025
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of atropine (target heart rate 100 beats/min)
Trial: 8038025
Drug: Additional infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Additional infusion of adrenaline and noradrenaline
Trial: 3524645
Drug: Magnesium supplementation
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium supplementation (both intravenous and oral)
Trial: 28279428
Drug: Nadroparin (2850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadroparin (2850 IE anti‐Xa=0.3ml daily subcutaneous self-injection)
Trial: 28279428
Drug: Fondaparinux (2.5mg=0.5ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fondaparinux (2.5mg=0.5ml daily subcutaneous self-injection)
Trial: 23469888
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg single oral dose of memantine
Trial: 27653085
Drug: MedGem (MG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MedGem (MG)
Trial: 17062805
Drug: MedGem (MG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MedGem (MG) sitting position
Trial: 17062805
Drug: MedGem (MG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MedGem (MG) supine position
Trial: 10935781
Drug: Insulin(GIK)
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin(GIK)
Trial: 8967706
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate (1000 mg/d) and vitamin D3 (500 IU/d)
Trial: 1390144
Drug: Roxithromycin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxithromycin (150 mg b.i.d. orally)
Trial: 1390144
Drug: Penicillin (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penicillin (2.5 MU x 8 daily intravenously, then 6 MU daily orally)
Trial: 2983909
Drug: High-dose naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose naloxone (5.4 mg/h)
Trial: 2983909
Drug: Low-dose naloxone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose naloxone (0.8 mg/h)
Trial: 23302973
Drug: Subcutaneous etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous etanercept 50 mg administered 90 minutes before surgery
Trial: 18164672
Drug: rhGH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH treatment (4.5 IU intramuscularly daily for 4 weeks)
Trial: 16505196
Drug: Carotid augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carotid augmentation index
Trial: 15243933
Drug: CVD 909
RxNorm normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVD 909 (oral attenuated typhoid vaccine) at doses of 10(6-9) cfu
Trial: 10211027
Drug: Nafamostat 0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafamostat 0.02 mg kg‐1
Trial: 10211027
Drug: Control (5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (5% glucose 0.02 ml kg‐1)
Trial: 7943305
Drug: Daily rhGH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily rhGH (0.15 mg somatotropin · kg‐1 · day‐1) intramuscular injections
Trial: 7943305
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition with daily rhGH
Trial: 31419155
Drug: Verb Network
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verb Network Strengthening Treatment (VNeST), 15 hours of therapy delivered by experienced speech-language pathologists.
Trial: 31419155
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy (as part of the study condition).
Trial: 31419155
Drug: Distributed therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distributed therapy (as part of the study condition).
Trial: 24595305
Drug: Ingestion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingestion of 15 g of whey protein after REX in ED
Trial: 24595305
Drug: Ingestion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingestion of 30 g of whey protein after REX in ED
Trial: 20146794
Drug: Transmural nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transmural nutritional support (energy and protein enriched diet, two additional servings of an oral nutritional supplement, vitamin D and calcium supplementation, consultations by a dietitian)
Trial: 12788879
Drug: GLP-1 infusion
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 infusion at 0.4 pmol/kg x min
Trial: 12788879
Drug: GLP-1 infusion
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 infusion at 0.8 pmol/kg x min
Trial: 12788879
Drug: GLP-1 infusion
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 infusion at 1.2 pmol/kg x min